
zzso zzso zzso expression competitively zzso the zzso zzso activity of zzso zzso protein zzso and zzso zzso IV zzso This zzso study was conducted to evaluate the safety of zzso in patients receiving zzso chemotherapy and to assess its effects on zzso zzso was administered orally for 7 days as a 200 zzso 400 zzso 800 zzso or 1,200 zzso total daily dose zzso twice zzso to 6, 6, 17, and 5 patients, zzso Patients received 2 cycles of zzso The first cycle served as each individual patient's zzso Patients had to develop Grade zzso zzso in zzso 1 in order to receive zzso in zzso zzso Most patients received zzso on Days zzso of chemotherapy in zzso 2, except at 800 zzso where an additional cohort zzso zzso 8) was treated on a Days 5-11 zzso Five of 7 patients receiving 800 zzso on Days zzso experienced a zzso improvement in Grade zzso zzso in zzso 2 versus zzso zzso Overall, zzso was well zzso A reduction in zzso zzso zzso fatigue, zzso and zzso was noted in patients receiving zzso zzso zzso zzso zzso and zzso were the most common zzso adverse events considered related to zzso Two Grade 3 adverse events were considered related to zzso zzso zzso zzso and zzso zzso zzso zzso A maximum tolerated dose was not zzso Given the accelerated zzso recovery, zzso evidence of zzso activity, and tolerable zzso of zzso additional studies to zzso the zzso dosing schedule in patients receiving zzso chemotherapy are zzso 

